CL2017000505A1 - Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016). - Google Patents

Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).

Info

Publication number
CL2017000505A1
CL2017000505A1 CL2017000505A CL2017000505A CL2017000505A1 CL 2017000505 A1 CL2017000505 A1 CL 2017000505A1 CL 2017000505 A CL2017000505 A CL 2017000505A CL 2017000505 A CL2017000505 A CL 2017000505A CL 2017000505 A1 CL2017000505 A1 CL 2017000505A1
Authority
CL
Chile
Prior art keywords
sulfamide
div
pyrimidin
sol
elaboration
Prior art date
Application number
CL2017000505A
Other languages
English (en)
Inventor
Stefan Abele
Jacques Alexis Funel
Ivan Schindelholz
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2017000505A1 publication Critical patent/CL2017000505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

<p>PROCESO PARA ELABORAR UN COMPUESTO DERIVADO DE PIRIMIDIN-SULFAMIDA Y EL USO DE UNO DE LOS INTERMEDIARIOS COMO TAL (DIV. SOL. 2008-2016).</p>
CL2017000505A 2014-02-14 2017-03-03 Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016). CL2017000505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14155137.4A EP2907811A1 (en) 2014-02-14 2014-02-14 Process for manufacturing pyrimidine sulfamide derivatives

Publications (1)

Publication Number Publication Date
CL2017000505A1 true CL2017000505A1 (es) 2017-11-24

Family

ID=50073084

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016002008A CL2016002008A1 (es) 2014-02-14 2016-08-10 Proceso para la elaboración de derivados de pirimidin sulfamida.
CL2017000505A CL2017000505A1 (es) 2014-02-14 2017-03-03 Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016002008A CL2016002008A1 (es) 2014-02-14 2016-08-10 Proceso para la elaboración de derivados de pirimidin sulfamida.

Country Status (28)

Country Link
US (1) US9938244B2 (es)
EP (3) EP2907811A1 (es)
JP (2) JP6431922B2 (es)
KR (2) KR102406358B1 (es)
CN (2) CN107162988B (es)
AR (2) AR099434A1 (es)
AU (2) AU2015217000B2 (es)
BR (2) BR122017005939B1 (es)
CA (1) CA2937277C (es)
CL (2) CL2016002008A1 (es)
CY (1) CY1123319T1 (es)
DK (1) DK3105220T3 (es)
EA (2) EA032460B1 (es)
ES (2) ES2819504T3 (es)
HK (1) HK1243405A1 (es)
HR (1) HRP20201450T1 (es)
HU (1) HUE050974T2 (es)
IL (1) IL251126A0 (es)
LT (1) LT3105220T (es)
MX (2) MX368014B (es)
NZ (1) NZ724273A (es)
PL (1) PL3105220T3 (es)
PT (1) PT3105220T (es)
SA (1) SA516371640B1 (es)
SG (2) SG10201701994RA (es)
SI (1) SI3105220T1 (es)
TW (2) TWI666203B (es)
WO (1) WO2015121397A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN105461639B (zh) * 2015-12-10 2018-03-09 合肥久诺医药科技有限公司 一种高纯度马西替坦的精制方法
CN105461638A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种马西替坦晶型及其制备方法
EP3658140B1 (en) * 2017-02-27 2025-05-21 Idorsia Pharmaceuticals Ltd Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
MY210547A (en) 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
CN114630668B (zh) * 2019-11-07 2024-02-27 苏州科睿思制药有限公司 一种Aprocitentan晶型及其制备方法和用途
WO2021237004A1 (en) * 2020-05-21 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技（台州）有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
AU2023275935A1 (en) 2022-05-25 2025-01-09 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2025102245A1 (zh) * 2023-11-14 2025-05-22 浙江天宇药业股份有限公司 一种双重内皮素受体拮抗剂阿普昔腾坦的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921918A1 (de) * 1989-07-04 1991-01-17 Hoechst Ag Verfahren zur herstellung von 2,4,6-trifluor-1,3,5-triazin
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
TR200103716A2 (tr) * 2001-12-25 2003-07-21 Ba�Lama Al� Zenginleştirilmiş dizel yakıt kompozisyonu
US7323465B2 (en) * 2002-01-02 2008-01-29 Actelion Pharmaceuticals Ltd. Alkansulfonamides as endothelin antagonists
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
WO2010144477A2 (en) * 2009-06-12 2010-12-16 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR101471047B1 (ko) * 2012-11-21 2014-12-08 주식회사 메디켐코리아 고순도 보센탄의 개선된 제조방법
CN103012279B (zh) * 2012-11-27 2015-01-28 浙江工业大学 一种4,5,6-三氟嘧啶化合物的制备方法
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives

Also Published As

Publication number Publication date
CN107162988A (zh) 2017-09-15
AU2015217000A1 (en) 2016-09-29
CA2937277A1 (en) 2015-08-20
SA516371640B1 (ar) 2019-09-08
MX2016010486A (es) 2016-10-31
MX368014B (es) 2019-09-13
KR20160122213A (ko) 2016-10-21
ES2819504T3 (es) 2021-04-16
JP2017125055A (ja) 2017-07-20
AU2017202446A1 (en) 2017-05-04
SG10201701994RA (en) 2017-05-30
KR20170029656A (ko) 2017-03-15
SG11201606667VA (en) 2016-09-29
AU2015217000B2 (en) 2019-02-14
AR107801A2 (es) 2018-06-06
EP3214082A1 (en) 2017-09-06
JP2017505801A (ja) 2017-02-23
HUE050974T2 (hu) 2021-01-28
NZ724273A (en) 2020-06-26
EP2907811A1 (en) 2015-08-19
BR122017005939A2 (pt) 2019-09-10
EA032460B1 (ru) 2019-05-31
JP6421209B2 (ja) 2018-11-07
EA201790343A1 (ru) 2017-06-30
JP6431922B2 (ja) 2018-11-28
US9938244B2 (en) 2018-04-10
HK1243405A1 (en) 2018-07-13
CN105992762B (zh) 2019-04-16
AU2017202446B2 (en) 2019-03-28
NZ729685A (en) 2020-11-27
EA032933B1 (ru) 2019-08-30
BR112016018581A2 (pt) 2017-08-08
CN107162988B (zh) 2020-08-21
MX377801B (es) 2025-03-11
TW201730157A (zh) 2017-09-01
TW201613877A (en) 2016-04-16
EP3105220A1 (en) 2016-12-21
CN105992762A (zh) 2016-10-05
PT3105220T (pt) 2020-09-23
DK3105220T3 (da) 2020-09-07
BR112016018581A8 (pt) 2021-06-22
EP3105220B1 (en) 2020-07-01
TWI663155B (zh) 2019-06-21
EA201691618A1 (ru) 2017-01-30
AR099434A1 (es) 2016-07-20
BR112016018581B1 (pt) 2022-11-16
KR102261695B1 (ko) 2021-06-07
IL251126A0 (en) 2017-04-30
ES2906458T3 (es) 2022-04-18
CL2016002008A1 (es) 2017-02-03
LT3105220T (lt) 2020-10-12
HRP20201450T1 (hr) 2020-12-25
EP3214082B1 (en) 2021-11-10
US20160368882A1 (en) 2016-12-22
SI3105220T1 (sl) 2020-10-30
TWI666203B (zh) 2019-07-21
CA2937277C (en) 2021-07-06
CY1123319T1 (el) 2021-12-31
PL3105220T3 (pl) 2020-12-28
WO2015121397A1 (en) 2015-08-20
KR102406358B1 (ko) 2022-06-07
BR122017005939B1 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
CL2016002021A1 (es) Ciclopropilaminas como inhibidores lsd1.
UY36311A (es) Indazoles sustituidos con bencilo
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
HRP20182073T1 (hr) Derivati kinoksalina korisni kao modulatori fgfr kinaze
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
DK3224256T3 (da) N-((het)arylmethyl)-heteroaryl-carboxamid-forbindelser som plasma kallikrein-inhibitorer
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
DK3539961T3 (da) Polycykliske amidderivativer som cdk9-inhibitorer
CR20170005A (es) Derivados de insoindolina
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
CL2016002008A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
UY36221A (es) Derivados de isoindolinona
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
CR20160448A (es) Nuevos derivados de piridina
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
CL2017000151A1 (es) Derivados de piridona